Donglin Sun | Prostate Cancer | Best Researcher Award

Posted on by Pencis

Dr. Donglin Sun | Prostate Cancer | Best Researcher Award

Southern Medical University | China

AUTHOR PROFILE

Scopus

🔬SUN DONGLIN – MEDICAL DOCTOR IN ONCOLOGY 

📚EARLY ACADEMIC PURSUITS 

Sun Donglin began his academic journey at No.1 Middle School of Fuyang, Anhui Province (2005-2008). His strong foundation in science led him to pursue a Bachelor’s Degree in Clinical Medicine at Bengbu Medical College (2008-2013), where he developed a keen interest in oncology. His dedication and passion for medical research culminated in a PhD in Oncology through the Master-Doctor Continuous Program at the Affiliated Cancer Hospital of Guangzhou Medical University (2018-2023). He was recognized as an “Outstanding Graduate Student” and “Excellent Graduate”, a testament to his academic excellence and research contributions.

🏥PROFESSIONAL ENDEAVORS 

Sun Donglin’s clinical training and professional career reflect a steady progression in expertise:

  • 2013 – 2016: Surgical Resident, Third Affiliated Hospital of Sun Yat-sen University – Gained hands-on experience in surgical oncology.
  • 2016 – 2018: Urology Resident Physician, Shenzhen Hospital of Southern Medical University – Developed a specialization in urological oncology.
  • 2023 – Present: Urology Associate Chief Physician, Shenzhen Hospital of Southern Medical University – Achieved Associate Chief Physician Certification in 2020, demonstrating his leadership in urologic oncology and clinical excellence.

🔍RESEARCH FOCUS 

Sun Donglin’s research focuses on two critical areas in oncology:

  1. Mechanisms of Non-Canonical NF-κB Signaling in Renal Fibrosis – Investigating how alternative pathways of NF-κB contribute to fibrosis, which has significant implications for kidney disease treatments.
  2. Drug Resistance Mechanisms in Prostate Cancer – Exploring molecular resistance pathways in prostate cancer to enhance therapeutic strategies and overcome treatment barriers.

💡CONTRIBUTIONS TO SCIENTIFIC RESEARCH 

Sun Donglin has led and participated in several high-impact research projects:

  • Principal Investigator:

    • National Natural Science Foundation of China (Youth Program) – 300,000 RMB (2025-2027) (Approval No.: 82400789)
    • Guangdong Provincial Medical Science and Technology Research Fund – 10,000 RMB (2024-2026) (Approval No.: A2024317)
    • Southern Medical University National Natural Science Foundation Cultivation Program – 100,000 RMB (2024-2026) (Approval No.: 23H3AGZR02)

  • Key Participant in Major Research Projects:

    • National Natural Science Foundation of China Major Research Program Cultivation Project – 680,000 RMB (2020-2022) (Approval No.: 91949102)
    • National Natural Science Foundation of China General Program – 570,000 RMB (2019-2022) (Approval No.: 81874095)

🌍IMPACT AND INFLUENCE 🌍

Sun Donglin’s research has contributed to a deeper understanding of renal fibrosis mechanisms and drug resistance in prostate cancer. His work has the potential to improve therapeutic interventions and patient outcomes, particularly in treatment-resistant prostate cancer cases. His collaborations in major national projects highlight his role as an emerging leader in oncological research.

🏅ACADEMIC CITES AND RECOGNITION 

  • Recognized as an Outstanding Graduate Student and Excellent Graduate during his PhD.
  • His research findings are gaining recognition in top-tier oncology journals, further solidifying his influence in the field.
  • Contributions to multi-million RMB-funded research projects, showcasing his ability to secure competitive grants.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Sun Donglin’s work will shape the future of oncology therapeutics and urological oncology. His research on non-canonical NF-κB signaling could unlock new pathways for renal fibrosis treatment, while his studies on prostate cancer drug resistance could lead to novel therapeutic strategies.

Moving forward, he aims to:
✅ Expand research collaborations internationally to enhance the impact of his studies.
✅ Develop translational therapies targeting NF-κB signaling in fibrosis and prostate cancer.
✅ Mentor young oncologists and researchers to foster the next generation of medical scientists.

🌍CONCLUSION 

Dr. Sun Donglin is a rising leader in oncology research and urological oncology, with a strong foundation in both clinical practice and scientific innovation. His expertise in non-canonical NF-κB signaling in renal fibrosis and drug resistance in prostate cancer has positioned him as a key contributor to the advancement of cancer therapeutics.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression
    Authors: Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., Qian, G., Li, C., Zhang, H., Jiang, Y., Ye, D., Liu, D., Hu, Y., Wang, J., Chen, W., Zhao, Q., Zeng, M., Zhang, J., Wang, L., & Zhang, X
    Journal: Clinical and Translational Medicin
    Year: 2021

 

  • Title: B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3.
    Authors: Qian, G., Jiang, W., Sun, D., Sun, Z., Chen, A., Fang, H., Wang, J., Liu, Y., Yin, Z., Wei, H., Fang, H., & Zhang, X.
    Journal: Cellular & Molecular Immunology
    Year: 2023

 

  • Title: Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-κB Signaling with Antitumor Efficacy
    Authors: Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., Liu, S., Liu, Y., Jiang, Y., Zhu, W., & Zhang, X.
    Journal: Molecular Therapy
    Year: 2025

 

  • Title: LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization.
    Authors: Liang, W., Wu, H., Long, Q., Lin, H., Lv, X., Ma, W., Wu, T., Ai, L., Zheng, Q., Guo, J., Chen, X., Guo, J., & Sun, D..
    Journal: Life Sciences
    Year: 2025

 

  • Title: Integrative analysis of potential diagnostic markers and therapeutic targets for glomerulus-associated diabetic nephropathy based on cellular senescence
    Authors: Sun, D., Wei, S., Wang, D., Zeng, M., Mo, Y., Li, H., Liang, C., Li, L., Zhang, J. W., & Wang, L
    Journal: Frontiers in Immunology
    Year: 2023

Dr. Fatemeh Kanaani Nejad – Breast Cancer Screening – Best Researcher Award

Posted on by Pencis

Dr. Fatemeh Kanaani Nejad - Breast Cancer Screening - Best Researcher Award

Anesthesiology and Critical Care Research Center - Iran

Author Profile

Google Scholar

EARLY ACADEMIC PURSUITS:

Fatemeh Kanaani Nejad was an academically driven individual from early on, demonstrating her commitment to education during her high school years at Farzanegan High School in Shiraz, Iran (2011-2014). Her consistent dedication and performance laid the foundation for her subsequent academic journey.

PROFESSIONAL ENDEAVORS:

After completing high school, Fatemeh pursued her Medical Doctor (MD) degree at Isfahan University of Medical Sciences, Isfahan, Iran, from February to July 2015. She continued her medical education at Shiraz University of Medical Sciences, Shiraz, Iran, graduating in February 2022. Following her academic achievements, she embarked on a postdoctoral research position at the Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, starting in September 2022.

CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER SCREENING

Fatemeh actively engaged in various workshops and certifications, showcasing her commitment to expanding her skill set. Notably, she participated in workshops such as Search, Study Design, and Proposal Writing, as well as Python training. Her research focus, primarily in the field of Anesthesiology and Critical Care, is evident in her contributions to poster presentations for the European Society of Radiology (ECR 2023). These contributions cover topics ranging from targeted ultrasound of the breast to the application of shear wave elastography in breast cancer screening.

IMPACT AND INFLUENCE:

Fatemeh's impact extends beyond her academic pursuits. Her poster presentation on "Anti-Inflammatory Therapy in Hair Loss Treatment" at The Second International Conference on Holly Prophet Mohammad’s Tradition reflects her engagement with interdisciplinary topics and potential implications for medical treatments.

ACADEMIC CITES:

While specific citation numbers are not provided, Fatemeh's work is disseminated through DOI-linked poster presentations. This suggests that her research is accessible and has the potential for citation within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Fatemeh's legacy is marked by her achievements as the first-ranked student in Farzanegan high school and the second-ranked student among Isfahan University of Medical Sciences students in 2015. Her mentorship role in the Medical Physics Research Center and continued contributions to conferences indicate a promising future of further academic and professional accomplishments.

NOTABLE PUBLICATIONS

Association of imaging and pathological findings of breast cancer in very young women: Report of a twenty-year retrospective study. 2024